Publications
166
Citations
2,387
Est. group size
—
Recurring co-author estimate
Active years
14
Publishing since 2013
Xiangnan Guan studies how tumors interact with their surrounding cellular environment and immune system, particularly in cancers like prostate cancer, multiple myeloma, and urothelial (bladder) cancer. Recent work focuses on how signaling pathways in tumor-supporting cells (such as fibroblasts) and hormone-related pathways affect tumor resistance to immunotherapy drugs like anti-PD-L1 treatments. This research aims to identify new drug targets and better understand why some cancers resist current immune-based treatments.
Publication output has grown substantially over the past decade, rising from near zero in 2017-2019 to a sharp peak in 2023, with continued high output through 2025-2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
Cancer Research · 2026
- Microenvironmentally derived fatty acid–binding proteins 4 and 5 are novel therapeutic vulnerabilities in multiple myeloma
Blood Neoplasia · 2026
- Data from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
2026
- Supplementary Table 1 from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
2026
- Supplementary Methods from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
2026
- Supplementary Figure 4 from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
2026
- Supplementary Figure 7 from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
2026
- Supplementary Figure 1 from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
2026
- Supplementary Figure 2 from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
2026
- Supplementary Table 2 from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
2026
- Supplementary Figure 6 from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
2026
- Supplementary Figure 3 from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
2026
- Supplementary Figure 5 from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
2026
- Supplementary Figure 4 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2026
- Supplementary Figure 5 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2026
- Cancer Research×6
- Nature×5
- Journal of Clinical Oncology×5
- bioRxiv (Cold Spring Harbor Laboratory)×4
- Proceedings of the National Academy of Sciences×3
- Timothy D. Gauntner
Medicine · The Ohio State University
- Paul Monk
Medicine · The Ohio State University
- Edmund Folefac
Medicine · The Ohio State University
- Adeoluwa A. Adeluola
Medicine · The Ohio State University
- Timothy H. Helms
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile